ANI Pharmaceuticals, Inc.（ANIP）财务数据ANIPANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (ANIP) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sales of Cortrophin Gel, accounting for 44.0% of total sales, equivalent to $117.13M. Other significant revenue streams include Generic pharmaceutical products and Sales of ILUVIEN and YUTIQ. Understanding this composition is critical for investors evaluating how ANIP navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ANI Pharmaceuticals, Inc. maintains a gross margin of 54.97%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.97%, while the net margin is 9.29%. These profitability ratios, combined with a Return on Equity (ROE) of 19.26%, provide a clear picture of how effectively ANIP converts its operational activities into shareholder value.

In the context of the broader market, ANIP competes directly with industry leaders such as ANAB and LKFT. With a market capitalization of $1.76B, it holds a significant position in the sector. When comparing efficiency, ANIP's gross margin of 54.97% stands against ANAB's 100.00% and LKFT's 25.95%. Such benchmarking helps identify whether ANI Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

ANI Pharmaceuticals has shown strong revenue growth, with Q2 2026 revenue at $266 million, a 25.9% increase year-over-year. Net income for Q2 was $24.71 million, translating to an EPS of $1.05, a significant improvement from last year's $0.36. The gross margin has also improved to 54.97% in Q2 2026, indicating effective cost management and operational efficiency.